Table 3 Treatment strategies used among patients with non-metastatic breast cancer
Variable | Category | Frequency (%) |
|---|---|---|
Surgery | Yes | 258(99.2) |
| Â | No | 2(0.8) |
| Â | Â | 260(100) |
Type of surgery | Radical mastectomy | 187(72.5) |
| Â | Breast conserving surgery | 71(27.5) |
| Â | Â | 258(100) |
*Axillary lymph node dissection | Yes | 210(81.4) |
| Â | No | 48(18.6) |
| Â | Â | 258(100) |
Chemotherapy | Yes | 147(56.5) |
| Â | No | 113(43.5) |
| Â | Â | 260(100) |
Type | Neoadjuvant | 14(9.5) |
| Â | Adjuvant | 107(72.8) |
| Â | Both | 26(17.7) |
| Â | Â | 147(100) |
Drug combination | Cyclophosphamide + Doxorubicin + 5-Fluorouracil | 120(82) |
|  | Cyclophosphamide + Methotrexate + 5-Fluorouracil | 7(4.8) |
|  | Docetaxel + Doxorubicin + Cyclophosphamide | 4(2.7) |
| Â | OTHERS | 16(10.8) |
| Â | 147(100) | |
Hormone therapy | Yes | 129(49.8) |
| Â | No | 131(50.4) |
Type | Anastrozole | 7(5.4) |
| Â | Tamoxifen | 122(94.6) |
| Â | Â | 129(100) |
Duration | 5years | 13(100) |
Radiation therapy | Yes | 201(77.3) |
| Â | No | 59(22.7) |
| Â | Â | 260(100) |
Duration | 5Â weeks | 178(88.6) |
| Â | 6Â weeks | 20(10.0) |
| Â | 9Â weeks | 2(1.0) |
| Â | 10Â weeks | 1(0.5) |
| Â | Â | 201(100) |
Treatment combination | Â | |
Surgery + chemotherapy + radiation therapy | Â | 66(25.7) |
Surgery + chemotherapy + radiation therapy + hormonal therapy |  | 63(24.1) |
Surgery + radiation therapy + hormonal therapy |  | 50(19.5) |
Surgery alone | Â | 32(12.5) |
Surgery + radiation therapy | Â | 20(7.8) |
Surgery + chemotherapy | Â | 12(4.7) |
Surgery + hormonal therapy | Â | 11(3.9) |
Surgery + chemotherapy + hormonal therapy |  | 6(2.0) |
| Â | Â | 260(100) |